QIAGEN (QGEN)
Supplies sample technologies, molecular diagnostics, PCR and genomics tools for research and clinical testing.
Something off on this page? Send us feedback.
Sells consumables, instruments and software that move biological samples from preparation through molecular analysis. Its workflow serves life-science research and clinical diagnostics, with sample technologies, diagnostic solutions, PCR and genomics as core pillars.
Connects sample technologies, diagnostic solutions, PCR and nucleic-acid amplification, genomics and NGS, plus related software and automation. QuantiFERON, QIAstat-Dx and QIAcuity are current pillars within workflows that take biological samples from preparation through molecular analysis. Built from a nucleic-acid preparation base, the portfolio now extends into assays, instruments and data interpretation.
Serves life-science customers in academia, pharmaceutical R&D, industrial work and forensics, alongside clinical healthcare customers. Operations are international across more than 35 locations. The business depends on combining sample preparation, assays, bioinformatics and automation within one Sample to Insight workflow.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2026 | UBS | Initiate | Rating: —Target: $52 | Target: $47 |
| Aug 7, 2026 | Stifel Nicolaus | Target | Target: $36 | Target: $40 |
| Aug 7, 2026 | Barclays | Reiterate | Rating: —Target: $38 | Target: $40 |
| Aug 6, 2026 | Jefferies | Reiterate | Rating: —Target: $59 | Target: $48 |
| Jul 14, 2026 | Berenberg Bank | Target | Target: — | Target: $45.50 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $793.5M · Total debt $1.64B · Total assets $5.89B · Shareholders' equity $3.36B
- Revenue
- $535.0M
- Operating income
- $132.4M
- Net income
- $103.4M
HistoryDividendAnnual yield
| Institutions | ≈ 66.01% | 143.19M ADS | |
|---|---|---|---|
| 364 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Other | ≈ 33.99% | 73.73M ADS | |
| remainder | |||
216.92M ADS as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
PRIMECAP Management CompanyInstitution | 6.88% | 14.92M | filed Feb 12, 2020 |
Wellington Management Group LLPInstitution | 5.72% | 12.41M ADS | as of Jun 30, 2026 |
Price T Rowe Associates Inc /MD/Institution | 5.23% | 11.35M ADS | as of Jun 30, 2026 |
Principal Financial Group IncInstitution | 3.07% | 6.65M ADS | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 2.86% | 6.21M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Thermo Fisher Scientific
Overlaps in sample prep, PCR, and end-to-end genomics
- Danaher
Overlaps in sample-to-answer PCR and clinical molecular testing
- Bio-Rad Laboratories
Direct digital-PCR rival with a broad ddPCR assay portfolio
- Illumina
NGS platforms, library prep, and analysis overlap in genomics
- Agilent Technologies
Overlaps in genomics tools, qPCR, and clinical-lab workflows
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| QIAGEN | $44.03 | −1.69% | $9.24B | 23.0 | 17.6 | 4.4 | +0.3% |
| Thermo Fisher Scientific | $657.96 | −0.12% | $244.81B | 35.4 | 25.1 | 5.3 | +10.5% |
| Danaher | $218.19 | +1.09% | $151.67B | 38.3 | 24.7 | 6.0 | +5.5% |
| Bio-Rad Laboratories | $378.46 | +0.30% | $10.16B | 45.7 | 36.7 | 3.9 | −0.1% |
| Illumina | $243.30 | +1.88% | $36.13B | 44.6 | 42.6 | 8.0 | +9.4% |
| Agilent Technologies | $164.61 | +1.65% | $45.75B | 31.9 | 25.1 | 6.2 | +8.1% |
| Median | 38.3 | 25.1 | 6.0 | +8.1% |